File photo
File photo
Approximately $265 million in CARES Act funding will be allocated among two Texas entities for the mass production of a COVID-19 vaccine.
The federal government will partner with the Texas A&M University System Center for Innovation in Advanced Development & Manufacturing and FUJIFILM Diosynth Biotechnologies of Texas to make 100 million doses of a vaccine being developed by Novavax.
The $265 million contract is part of President Donald Trump administration’s Operation Warp Speed initiative and is derived from a $3.5 billion public-private funding allocation included in the CARES Act.
Rep. Bill Flores (R-Texas) anticipates the positive impact the partnership could bring to Texas and its 17th Congressional district.
“President Trump’s announcement is great news for Texas, the Brazos Valley, and hardworking American families in the fight against COVID-19,” Flores said in a news release.
He added that the Novavax vaccine is in the second phase of clinical trials.
Alerts Sign-up